File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Rosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression

TitleRosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression
Authors
Chen, BLYu, JZeng, ZRChu, WKWong, CYPCheng, YYSung, JJYHu, PJLeung, WK
KeywordsPeroxisome proliferator-activated receptors
Rosiglitazone
Issue Date2008
PublisherDemetrios A Spandidos Ed & Pub. The Journal's web site is located at http://147.52.72.117/OR/or.htm
Citation
Oncology Reports, 2008, v. 20 n. 5, p. 1093-1097 How to Cite?
DOI: http://dx.doi.org/10.3892/or_00000114
AbstractOur previous study demonstrated that PPARγ ligand rosiglitazone prevents gastric carcinogenesis in rats induced by chemical carcinogen N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). In this study, we attempted to identify novel anticancer mechanisms of rosiglitazone. By examining the gene expression profiles of MNNG-induced and rosiglitazonetreated gastric cancer with Uniset Rat I Bioarray microarray, we identified a gene that showed prominent responses in the rosiglitazone-treated group. The hypertension-related, calcium-regulated gene (HCaRG) was significantly upregulated in rat gastric carcinoma of the rosiglitazone-treated group when compared with the MNNG group. We further examined HCaRG expression in human gastric cancer and found that the expression of HCaRG was down-regulated in human gastric cancerous tissue. Rosiglitazone markedly induced the expression of HCaRG in the AGS cell line. The up-regulation of HCaRG may be one of the mechanisms underlying the chemopreventive effect of rosiglitazone in gastric cancer.
Persistent Identifierhttp://hdl.handle.net/10722/163220
ISSN
1021-335X
2023 Impact Factor: 3.8
2023 SCImago Journal Rankings: 0.864
ISI Accession Number ID
WOS:000260648200014
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorChen, BLen_US
dc.contributor.authorYu, Jen_US
dc.contributor.authorZeng, ZRen_US
dc.contributor.authorChu, WKen_US
dc.contributor.authorWong, CYPen_US
dc.contributor.authorCheng, YYen_US
dc.contributor.authorSung, JJYen_US
dc.contributor.authorHu, PJen_US
dc.contributor.authorLeung, WKen_US
dc.date.accessioned2012-09-05T05:28:52Z-
dc.date.available2012-09-05T05:28:52Z-
dc.date.issued2008en_US
dc.identifier.citationOncology Reports, 2008, v. 20 n. 5, p. 1093-1097en_US
dc.identifier.issn1021-335Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/163220-
dc.description.abstractOur previous study demonstrated that PPARγ ligand rosiglitazone prevents gastric carcinogenesis in rats induced by chemical carcinogen N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). In this study, we attempted to identify novel anticancer mechanisms of rosiglitazone. By examining the gene expression profiles of MNNG-induced and rosiglitazonetreated gastric cancer with Uniset Rat I Bioarray microarray, we identified a gene that showed prominent responses in the rosiglitazone-treated group. The hypertension-related, calcium-regulated gene (HCaRG) was significantly upregulated in rat gastric carcinoma of the rosiglitazone-treated group when compared with the MNNG group. We further examined HCaRG expression in human gastric cancer and found that the expression of HCaRG was down-regulated in human gastric cancerous tissue. Rosiglitazone markedly induced the expression of HCaRG in the AGS cell line. The up-regulation of HCaRG may be one of the mechanisms underlying the chemopreventive effect of rosiglitazone in gastric cancer.en_US
dc.languageengen_US
dc.publisherDemetrios A Spandidos Ed & Pub. The Journal's web site is located at http://147.52.72.117/OR/or.htmen_US
dc.relation.ispartofOncology Reportsen_US
dc.subjectPeroxisome proliferator-activated receptors-
dc.subjectRosiglitazone-
dc.subject.meshAnimalsen_US
dc.subject.meshAntineoplastic Agents - Pharmacologyen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshDown-Regulationen_US
dc.subject.meshGene Expressionen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshMethylnitronitrosoguanidine - Toxicityen_US
dc.subject.meshNuclear Proteins - Biosynthesis - Drug Effects - Geneticsen_US
dc.subject.meshOligonucleotide Array Sequence Analysisen_US
dc.subject.meshRatsen_US
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_US
dc.subject.meshStomach Neoplasms - Drug Therapy - Metabolismen_US
dc.subject.meshThiazolidinediones - Pharmacologyen_US
dc.subject.meshUp-Regulationen_US
dc.titleRosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expressionen_US
dc.typeArticleen_US
dc.identifier.emailLeung, WK:waikleung@hku.hken_US
dc.identifier.authorityLeung, WK=rp01479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.3892/or_00000114en_US
dc.identifier.pmid18949406en_US
dc.identifier.scopuseid_2-s2.0-58149329042en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-58149329042&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume20en_US
dc.identifier.issue5en_US
dc.identifier.spage1093en_US
dc.identifier.epage1097en_US
dc.identifier.isiWOS:000260648200014-
dc.publisher.placeGreeceen_US
dc.identifier.scopusauthoridChen, BL=25122481900en_US
dc.identifier.scopusauthoridYu, J=35351306800en_US
dc.identifier.scopusauthoridZeng, ZR=7402647305en_US
dc.identifier.scopusauthoridChu, WK=25947277800en_US
dc.identifier.scopusauthoridWong, CYP=25947838400en_US
dc.identifier.scopusauthoridCheng, YY=37093696600en_US
dc.identifier.scopusauthoridSung, JJY=36847007300en_US
dc.identifier.scopusauthoridHu, PJ=7201989582en_US
dc.identifier.scopusauthoridLeung, WK=7201504523en_US
dc.identifier.issnl1021-335X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats